Immunotherapy with chemotherapy for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (benmelstobart) with chemotherapy, and sometimes another drug (anlotinib), for people with limited-stage small cell lung cancer. The goal is to see if this treatment helps shrink or control the cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have limited-stage small cell lung cancer that can still be removed with surgery.
- You may have had only one round of chemo – no other cancer treatments yet.
- You need to be in good overall health (able to do daily activities) with no major heart, liver, or kidney problems.
- You cannot have untreated cancer spread to the brain or other serious conditions like uncontrolled bleeding or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination treatment for early-stage small-cell lung cancer. It compares giving immunotherapy drugs (PD-1/PD-L1 inhibitors) along with chemotherapy before surgery versus chemotherapy alone, to see if the combination helps shrink tumors more effectively and improves outcomes.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery, followed by surgery and radiation, is effective for limited-stage small cell lung cancer. The goal is to see if this approach helps control the cancer better than standard treatment alone.
This trial tests a new combination of an immunotherapy drug, a targeted therapy, and standard chemotherapy plus radiation for people with limited-stage small cell lung cancer. It aims to see if this combination improves outcomes compared to standard treatment alone.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.